| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Tourette Syndrome | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Syndrome | |||||
| 3 | More general conditions related to this trial | ||||
| Basal Ganglia Diseases | |||||
| Brain Diseases | |||||
| Central Nervous System Diseases | |||||
| Disease | |||||
| Genetic Diseases, Inborn | |||||
| Heredodegenerative Disorders, Nervous System | |||||
| Mental Disorders | |||||
| Mental Disorders Diagnosed in Childhood | |||||
| Movement Disorders | |||||
| Nervous System Diseases | |||||
| Neurodegenerative Diseases | |||||
| Pathologic Processes | |||||
| Tic Disorders | |||||
| 4 | Interventions listed in this trial | ||||
| pramipexole IR | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Pramipexol | |||||
| 6 | More general drug interventions related to this trial | ||||
| Anti-Dyskinesia Agents | |||||
| Antioxidants | |||||
| Antiparkinson Agents | |||||
| Central Nervous System Agents | |||||
| Dopamine Agents | |||||
| Dopamine Agonists | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Protective Agents | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Boehringer Ingelheim Pharmaceuticals | |||||
|
